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Summary Investigation of genetic changes in tumours by loss of heterozygosity (LOH) is a powerful
technique for identifying chromosomal regions that may contain tumour suppressor genes. LOH has been
described on chromosome 6 in ovarian carcinoma using restriction fragment length polymorphism analysis
with a small number of probes. We studied 29 ovarian carcinomas with 19 probes mapping to chromosome 6.
Sixteen of the 29 tumours showed LOH on 6q (55%). Of these 16, 63% showed loss of all informative
markers on that arm. One tumour showed loss of 6q24-qter, localising the putative tumour suppressor gene to
that region. Loss on 6p was 28% overall. However, using three dinucleotide repeat primer pairs from 6p to
study LOH in seven selected tumours, LOH was demonstrated at both 6p22.3-pter and at 6pl2-6p22. These
results confirm that 6q harbours a tumour suppressor gene of relevance to ovarian carcinoma and suggest that
there may also be a similar gene(s) on 6p. By Southern analysis, there was no evidence of genomic
rearrangements of the oestrogen receptor gene, located at 6q25.1. LOH on 6q was more common in high than
low grade tumours. The relevance of our findings to previous work in ovarian cancer and other solid tumours
is discussed.
Despite advances in chemotherapy for solid tumours in the
past decade or so, the outlook for those women with advanc-
ed ovarian cancer remains dismal. Because of its late presen-
tation, the overall 5 year survival is around 28%, whilst
early-stage disease has a much better prognosis (Slevin,
1986). It is now clear that uncovering genes that are responsi-
ble for the development and progression of ovarian cancer
may have importance diagnostic and therapeutic implica-
tions. With this in mind, we have studied ovarian carcinoma
(OC) using the well established technique of looking for loss
of one allele of a heterozygous restriction fragment length
polymorphism (RFLP) in matched tumour and normal
material from the same patient. Many publication's have
documented LOH in cancers and this approach has lead to
the cloning of a number of tumour suppressor genes that are
important in the development and progression of both
inherited and sporadic cancers (Weinberg, 1991). The original
'two-hit' hypothesis of Knudson (1971) was first confirmed in
retinoblastoma by the cloning of the Rb gene (Friend et al.,
1986), with the finding that a germline mutation constituted
the first 'hit', to be followed by a second, somatic inactiva-
tion of the gene, which was usually detectable by RFLP
analysis of filters of DNA from matched normal-tumour
pairs. More recently, it has been shown that some families
with retinoblastoma share a common mutation that can be
traced from affected parent to affected child. In these cases,
the other allele is lost or inactivated in various ways that
differ in different affected family members (Phillips et al.,
1991).
For soine years there has been considerable cytogenetic
evidence that in OC, one chromosome 6, particularly the
long arm, is missing in part or in whole (Mitelman, 1991).
Wake et al. (1980) demonstrated a clonal t(6;14),(q21;q24)
translocation, thus focusing attention on 6q21. A large cyto-
genetic study published recently has shown that alterations in
6q are common in OC, often in the setting of a highly
disorganised karyotype (Pejovic et al., 1992). Of 35 tumours
that had clonal chromosomal aberrations, ten had deletions
or unbalanced translocations involving 6q. Of these ten,
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seven had breakpoints between 6q21 -23, thus loss of the
long arm telomeric to this region was the commonest single
abnormality of chromosome 6 in this study. Despite the
common occurrence of aneuploidy, Atkin et al. (1983) show-
ed that one copy of 6q may be lost in early stage tumours,
when the karotype is relatively undisturbed. These data have
been followed up more recently by molecular studies of LOH
that have broadly confirmed the cytogenetic findings (Ehlen
& Dubeau, 1990; Lee et al., 1990).
Further data are now needed to accurately define regions
of LOH, so that efforts can be concentrated on cloning genes
in the relevant region of chromosome 6. Therefore we have
studied 29 pairs of matched malignant tumour and normal
DNA with ten DNA markers that detect polymorphic
sequences on 6q and six that do so on 6p. We also used the
centromeric marker p308 (D6ZJ). Oka et al. (1991) showed
that by using carefully dissected tumours it was possible to
reliably demonstrate LOH by PCR. Subsequently dinucleo-
tide (microsatellite) repeats mapping to chromosome 17 were
used to successfully demonstrate LOH in breast cancer
(Futreal et al., 1992). Therefore we included the dinucleotide
repeats D6S89 and FTHPI, which were utilised to study the
regions 6p22.3-23 and 6pl2-21 respectively by PCR-LOH.
From the use of these eight 6p probes in all the tumours, we
selected seven tumours for a more extensive analysis with
three further dinucleotide repeats mapping to the region
6pl2-6p23. We also included 12 nonmalignant ovarian tissue
specimens in our RFLP analysis. Although not all these
samples were analysed with all 18 probes, probes at 6p2l,
6q21 and 6qter were employed. In addition, we used probes
mapping to chromosome 10p, 10q and 16q to study all of the
malignant tumours to ensure that the losses seen were not
random.
Materials and methods
Materials
Tumours were collected from consenting patients undergoing
surgery for ovarian cancer. Lymphocytes were extracted from
blood taken at the time or within a few days of the oper-
ation. These patients were unselected and were operated on
at a number of hospitals in and around London. Tumour
tissue was initially dissected, and then frozen in isopentane
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before storing the samples in liquid nitrogen. Frozen sections
were then taken from representative parts of the tumour and
stained with haematoxylin and eosin. The proportion of
tumour to stroma was recorded. Three examples are shown
in Figure 1. The frozen sections allowed us to select the most
tumour-rich part of the specimen for further analysis. Class-
Table I Grading of tumours. This grading system is based on the
WHO international classification of tumours (Serov et al., 1973), with
modifications adapted from Russell (1987) and Anderson (1991). The
criteria chosen reflect reproducible observations, and by using five
criteria, the problems of bias are diminished
Score
Moderate/
Good Variable Poor
Criteriaa
1. Degree ofpapillary/glandular 2 4 6
formation
2. Cytological differentiation 2 4 6
3. Maximum mitotic index 1 2 3
4. Necrosis 1 2 3
5. Nuclear morphology 1 2 3
Scoring systemb
Grade I Total score = 7-11
Grade II Total score = 12-16
Grade III Total score = 17-21
aCriteria 1 and 2 are weighted more than criteria 3 to 6 as these two
features aremorereliable indicators. bIfthere isanyuncertainty overthe
finalscorethenanothersectionfromthesametumourwasanalysed, and
theaveragescoretaken. Sometumoursstillstradledtwogrades,andthis
is shown in Table II.
ification of the ovarian tumours by histopathological grade
was carried out according to the World Health Organisation
classification (Serov et al., 1973), with modifications based on
Russell (1987) and Anderson (1991). This method of classifi-
cation is reproducible and the criteria are set out in Table I,
and Table II lists all the tumours studied by tumour type,
grade, stage and percentage tumour in each sample used to
isolate DNA.
DNA extraction
DNA was extracted from the tumours using a modified
version of the protocol of Goelz et al. (1985). Instead of
using phenol-chloroform in the final stages, we used salt-
chloroform, according to the method of Mullenbach et al.
(1989). Lymphocyte DNA was also extracted using the salt-
chloroform method.
DNA probes and dinucleotide repeatprimerpairs*
Those used were: pMS29 (D6SF2JSJ) (6p25-pter), D6S202
(6p22.3-23), D6S89 (6p22.3-23), D6S109 (6p22), D6S105
*The new assignments for D65202, D6589, D65109, MYB, nSOD2,
and ESR are from data presented by Drs H.Y. Zoghbi, P.H. Rao, J.
Trent and J.M. Boyle at the First International Workshop on
Chromosome 6, Ann Arbor, MI, June 7-9, 1992. The proceedings of
the workshop will be published in Cytogenetics and Cell Genetics.
Figure 1 a, Tumour 25; virtually all cells are malignant, this tumour shows LOH. b, Tumour 61; despite the low proportion of
tumour to stroma in this specimen, LOH is still demonstrated. This probably reflects the relatively poor cellularity of the stroma. c, Tumour 60, a borderline mucinous tumours; note the ribbon of epithelium, with the high proportion of stroma to tumour in this specimen. No LOH is seen. The bar represents 100 im in all three photographs.CHROMOSOME 6 IN OVARIAN CANCER 553
TableII Histological subtype, grade, percentage tumourandclinical stagefromthesamples
studied
Histological classification
Adenocarcinoma, undifferentiated lineage
Adenocarcinoma, undifferentiated lineage
Serous papillary adenocarcinoma
Serous papillary adenocarcinoma
Normal ovary
Mucinous cystadenocarcinoma
Serous cystadenoma
Benign teratoma
Papillary adenocarcinoma
Serous papillary cystadenocarcinoma
Adenocarcinoma, undifferentiated lineage
Serous papillary cystadenocarcinoma
Borderline mucinous tumour
Papillary carcinoma
Serous papillary cystadenocarcinoma
Serous papillary cystadenocarcinoma
Mucinous adenocarcinoma
Endometrioid adenocarcinoma
Serous papillary adenocarcinoma
Borderline serous tumour
Serous papillary adenocarcinoma
Borderline serous tumour
Endometriosis
Endometrioid adenocarcinoma
Serous adenocarcinoma
Endometrioid adenocarcinoma
Adenocarcinoma, undifferentiated lineage
Serous papillary adenocarcinoma
Mixed Mullerian tumour
Mucinous adenocarcinoma
Serous papillary adenocarcinoma
Thecoma
Borderline serous adenofibroma
Mucinous cystadenoma
Borderline mucinous tumour
Serous papillary adenocarcinoma
Adenocarcinoma, undifferentiated lineage
Mucinous adenocarcinoma
Mucinous cystadenoma
Serous papillary adenocarcinoma
Endometrioid adenocarcinoma
Gradea
3
3
3
3
3
2
3
3
3
2-3
2-3
2
2-3
3
3
3
2
2
3
1
2
2
3
3
3
2
Percentage
tumour"
80
50
50-60
75
45
<20
80
75
75
50
80-90
<25
45-50
75
80
50
50
75
20-30
90
45-50
<5
60
80
80
80
80
95
75
60
100
60
20-30
40-45
25-30
90
90
10- 15
80
85
Clinical
stagec
NA
NA
NA
NA
NA
NA
NA
III
III
III
NA
III
III
III
III
II
III
III
NA
IV
II
III
III
IV
III
II
II
III
II
aForthegradingsystem, seeTableI.bThepercentagetumourinthesampleusedtomakethe
DNA was estimated from frozen sections as described in Materials and methods. cStaging
based on FIGO classification, NA: not available.
(6p2l.3), p2lU (D6SJ14E) (6p2l.3), HLA-DQa (HLA-
DRAI) (6p21.3), pRTVI (HLA-DRP) (6p2l.3), FTHPI
(6pl2-21), Ki-rasl (RASKPI) (6pll -12), pGST2 (GST2)
(6pll-12), p308 (D6ZI), p327A (D6S125) (6pll-12), pCGCa
(HCGA) (6ql4-21), pHM2.6 (MYB) (6q23.3-q24), phMn
SOD4 (SOD2) (6q25), pOR3 (ESR) (6q25.1), pJCZ30
(D6S37) (6q27), pTcr66hl (TCP1O) (6q27), CEB3 (D6S132)
(6q27), CEB4 (D6S133) (6q27), pMS605 (D6S86) (6q27),
pMS614 (DJOS92) (lOplS), pEFD75.1 (DIOS25) (lOq26) and
p79-2-23 (D16S7) (16q24). The assignments for pCGa, pOR3
and pJCZ30 were based on Boyle et al. (1992), who also
found that the minisatellite probes pJCZ30, pYNZ132 and
pMCOB12 (D6S37, D6S44 and D6S48 respectively) pro-
duced virtually identical bands on Southern blots and as our
own data (Markie et al., 1992) showed that the probes
pJCZ30 and MCOB12 have an identical restriction pattern,
we decided to use pJCZ30 only for this study. The positions
of TCPIO and D6S86 has been inferred from linkage data
(Blanche et al., 1992; Markie et al., 1992). The 3.6 kb, 3.0 kb
and 2.6 kb BamHI bands seen on genomic Southern blots
with p308 (D6ZI), have been mapped to the centromere by
genetic means (Blanche et al., 1991).
Southern transfer, hybridisation and autoradiography
DNA was cut with restriction endonucleases and size frac-
tionated through agarose gels. Southern transfer was carried
out using a vacuum blotter (Hybaid, Middlesex, UK) onto
Hybond N+ (Amersham International, Bucks, UK) and hyb-
ridisation was carried out according to the manufacturers'
instructions. DNA probes were labelled with a-[32P] dCTP
using the random priming technique of Feinberg and Vogel-
stein (1983) and 1 x 106 c.p.m. per ml of hybridisation solu-
tion was added to the prehybridisation mix and the mixture
was shaken gently at 65°C overnight. The filters were washed
to 0.1 x SSC, 0.1% SDS at 65°C and exposed to Kodak
XAR-5 film for between 6 and 110 h at - 70°C. LOH was
scored on the basis of the percentage tumour in the sample
(see Table I), repeated hybridisation of the filter with control
chromosome probes and where there was doubt, densito-
metry was carried out using a LKB Ultrascan XL Laser
Densitometer.
Dinucleotide repeat analysis
Primers flanking highly polymorphic dinucleotide repeats at
the D6S202, D6S89, D6S109, D6S105 and FTHPI loci were
used in PCR of DNA from the normal-tumour matched
samples described above. The PCR conditions used were as
previously described (Litt & Luty, 1990; Le Borgne-Demar-
quoy et al., 1991; Mauvieux et al., 1991; Ranum et al., 1991;
Weber et al., 1991), with the following modifications. We
incorporated 1 jjCi 32P dCTP to the PCR volume of 25 yl to
label the products when using the repeats D6S202, D6S109,
Tumour
number
7
9
10
11
12
13
14
15
17
20
24
25
26
27
28
29
30
31
32
36
37
38
39
40
41
42
47
48
50
51
53
54
57
58
60
61
64
65
66
67
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D6S105 and FTHPI. In these cases, the dCTP was reduced
from 200ylM to 100tLM. Some reactions (D6S89, D6S202 and
FTHPI) also worked well without using radioisotopes and
where possible, non-radiolabelled PCRs were carried out.
Loading dye (0.25% bromophenol blue, 0.25% xylene
cyanol, 30% glycerol, 6 x) was added to the completed PCR
reactions. Non-radioactive samples (5-10 Il) were loaded
onto 10% non-denaturing 0.8 mm wedge polyacrylamide
gels, which were run at 200 volts for approximately 18 h at
room temperature. The gels were then stained in a buffered
bath containing 0.5 Lgml1 ethidium bromide for 30 min,
and the bands photographed on a U.V. transilluminator.
Radioactive samples (1-3;gl) were located onto 10% non-
denaturing 0.4 mm polyacrylamide gels and exposed to
Kodak XAR-5 film at room temperature for between 20 and
72 h.
Results
LOH on chromosome 6q
Where possible, all ten probes were used to study the 29
malignant tumours. The results are set out in Figure 2, and
representative autoradiographs are shown in Figure 3. We
have demonstrated that LOH of 6q probes is a common
occurrence, with 16/29 (55%) showing LOH of one or more
probes. As shown in Table III column 5, in those 16 tumours
with 6q LOH, the loss involved all informative markers in 10
(63%). However, Tumour 9 had LOH limited to probes
mapping distal to 6q24. This suggests that any tumour sup-
pressor genes relevant to OC on the long arm of chromosome
6 will be distal to MYB. The oestrogen receptor (ESR) gene
is an obvious candidtate for involvement in OC and when
heterozygosity was seen with the cDNA probe pOR3, LOH
on 6q always included the ESR gene. However, we did not
find any rearrangements of the gene by Southern blotting
using the pOR3 probe in any of the 41 pairs of samples when
digested with PvuII (data not shown). As shown in Table III,
there was no LOH with any chromosome 6q probe in any of
the nonmalignant tumours. Using minisatellite probes from
chromosome lOp, lOq and 16q, all of which map to the
telomeric regions of the respective chromosomal arms, we
have noted LOH in 4/18 (22%), 4/13 (31%) and 6/22 (27%)
cases respectively, compared with 14/23 (61%) seen at
D6SJ33, the most informative telomeric (minisatellite) 6q
probe. The averaged LOH seen with all four 6q telomeric
minisatellites is also 61% (46/75). This confirms that the
changes seen on chromosome 6q are nonrandom and are of
biological significance.
LOH on chromosome 6p
Six RFLP probes and two dinucleotide repeat primer pairs
from 6p were used to study the majority of the tumours. In
addition to these primers, three PCR primers from 6p were
used to study seven selected tumours. LOH on 6p was less
frequent than on 6q (8/29, 28%, Figures 2 and 4, Table III).
This is not significantly different from the loss seen on
chromosomes 10 and 16 and therefore may not in itself
suggest the presence of a tumour suppressor gene on 6p, but
two separate regions were involved, one between 6p22.3-pter
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Figure 2 An analysis of 29 tumours by RFLP DNA probes and two dinucleotide repeats (D6S89 and FTHPI). Ordinates: Probes
used, with their chromosomal location. Abcissae: Tumours studied by number. *The position of SOD2 with respect to ESR is not
known. §The order of TCP1O to D6S37 is not known.
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Figure 3 A selection of representative results from Figure 2 is shown. On the left is a karyogram with the approximate positions
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the karyogram. In each pair of bands, the left hand bands are normal tissue and the right, tumour. The loading for each pair is
equal to within 10%. The filled-in arrow indicates plasmid contamination and the open arrow draws attention to the retention of
MHC loci in some tumour cells within specimen 42. The full names of the probes and their chromosomal position is given in the
text.
(tumours 7, 10, 11, 42 and 64) and another at 6pl2-6p22
(tumours 7, 9, 10 and 42), which includes the major histo-
compatability complex (MHC) mapping within 6p2l.3. LOH
on 6p was always accompanied by LOH on 6q, but in only
50/o of cases was the reverse case (Figure 2 and Table III,
column 4). These numbers are small and require confirmation
in a larger series. As for 6q, there was no LOH on 6p in
nonmalignant tumours.
Dinucleotide repeat PCR-LOH
The results using the dinucleotide repeat primer pairs mapp-
ing to 6p in selected tumours are shown in Figure 4. Examples
of LOH are shown in the lower part of this Figure. As there
are potential quantitation problems with PCR, reactions
using the primers for D6S89 in the normal/tumour pairs 42
and 64 (showing no LOH and LOH respectively) were car-
ried out, with sampling at 15, 20, 25, 30, 35 and 40 cycles.
The relative intensity of the alleles in the normal/tumour
pairs remained unchanged (data not shown). We also used
primers flanking dinucleotide repeats on chromosome 17, in
regions known to show LOH by Southern blotting. Some
pairs that failed to show LOH on chromosome 6 clearly
demonstrated LOH when using the chromosome 17 primers
(data not shown). Thus the retention of heterozygosity on
chromosome 6 found in tumours at differing loci with differ-
ent dinucleotide repeats is likely to be a true biological
phenomenon rather than a false negative result due to co-
amplification of nonmalignant elements.
Complex events on chromosome 6
By using 19 probes we have shown that 2/8 cases (where
there is LOH with at least one probe on both arms) show
LOH of all informative markers on chromosome 6 (Table
III). Terminal and interstitial deletions of 6p were found,
sometimes in the same tumour (tumour 9: Figures 2-4). Two
tumours have LOH of 6q as well as having an extra copy of
6p. The extra copy of 6p in these two cases was confirmed by
densitometry (data not shown). There is one case of trisomy
6. Tumour 42 (Figure 3) shows virtually complete LOH at
both telomeres, but there is evidence from the DQa hybri-
disation that a significant proportion of the tumour cells in
this sample have retained both alleles in this region. There
was also retention seen in 6p22.3-23 with D6S89 (Figure 4).
Overall, our data show that there is independent LOH on
both chromosome arms, as well as complex events within the
retained sections.
LOH on chromosome 6 and histopathological grade
Figure 5 illustrates 6q LOH in terms of pathological grade
and histological subtypes. The grade 1 tumours contained
between 45 and 75% tumour, and since we have noted LOH
in some tumours where the proportion of tumour to stroma
is less than this (for example tumour 61, Figures 1 and 2),
the absence of loss is probably a true negative. On 6p, LOH
occurred in eight cases only; of these tumours, six were grade
3, and there was one tumour each in grades 2 and 2-3.
Whilst the numbes for 6p and 6q are small and do not allow
statistical analysis, they suggest that chromosome 6 LOH is
commoner in higher grade OCs. With regard to histological
subtype. Table III, column 3 shows that LOH on 6q is much
more frequent in serous and undifferentiated adenocarcin-
omas than in mucinous adenocarcinomas.
Discussion
We have shown that LOH on chromosome 6 is a common
phenomenon in OC. There are a number of chromosomal
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mechanisms by which LOH can occur, amongst the com-
monest being non-disjunction with or without reduplication
(Cavenee et al., 1983). In this case all informative markers on
the chromosome would show reduction to homozygosity,
with one or two copies of the retained chromosome, depend-
ing on whether or not reduplication occurred. As only two
out of eight cases with loss on 6p and q showed LOH of all
informative markers, non-disjunction is not the commonest
mechanism by which LOH occurs on chromosome 6 in OC.
Therefore mechanisms other than non-disjunction, such as
somatic recombination or deletion, must account for LOH
on chromosome 6 in OC. Three tumours (9, 10 and 42) have
interstitial deletions on 6p, which always include the MHC.
In addition to these deletions, these tumours have LOH of 6q
(Figures 2 and 4). In the 16 cases with LOH on 6q, eight had
LOH on 6p (Table III, column 4). However, 6p LOH was
always accompanied by LOH on 6q. This may imply some
disrupting effect of LOH on 6q on 6p or could be due to
chance.
Combining our findings with all the published data on
LOH of chromosome 6 in OC we can conclude that there is
at least one tumour suppressor gene between 6q24-qter and
based on three tumours in the studies of Dubeau and col-
leagues (Ehlen & Dubeau, 1990; Zheng et al., 1991), the gene
may be at 6q27. This gene is not restricted to any particular
histopathological type. There is probably at least one tumour
suppressor gene on 6p, both from our data and from that of
Sato et al. (1991). In their series of 37 tumours, this group
found that three out of the four tumours that had LOH on
6p and not 6q were non-serous tumours. However, we did
not find that 6p LOH was limited to nonserous tumours.
Loss of MHC loci, which may give a tumour a selective
advantage by escaping rejection by the immune system,
might explain the LOH at 6pl2-6p22 seen in our study, but
cannot account for the LOH seen at 6p22.3-pter. Thus other
genes on 6p are likely to be implicated in OC.
There appears to be a difference in LOH seen on chromo-
some 6p and q in Japanese and Caucasian populations. Sato
et al. (1991) found LOH on 6p in 6/12 cases using D6S29,
which maps just proximal to the MHC (Zoghbi et al., 1990),
but on 6q only 5/29 cases showed LOH. Studies of cauca-
sians give a different picture, with overall >50% LOH on 6q
and much less LOH on 6p (0/9, Lee et al., 1990; 8/29, this
study). It is not clear whether this is related to genetic
differences in the groups of women studied or is due to
technical differences between laboratories, which will dis-
appear as more tumours are studied.
Our data indicated that 6q LOH is more common in grade
3 tumours than in any other grade. Whether this implies that
6q LOH is a late event, or alternatively, that homozygous
loss of a 6q gene leads to a more aggressive tumour is not
known as there is debate about the origin, development and
subsequent course of an ovarian tumour in vivo (Anderson,
1990, ppl87-190; Fox, 1990a, ppl65-167; Fox, 1990b,
ppl85-186). We have not seen any LOH on 6p or 6q in
benign tumours. However, Russell et al. (1990) noted LOH
on chromosome 17q in one benign ovarian tumour. We have
demonstrated that LOH is more likely to occur in serous and
undifferentiated adenocarcinomas than in the mucinous type,
but interpretation of these results should be cautious, as three
of the four mucinous tumours are grade 1 and therefore the
true reason for the absence of LOH may be the low grade
rather than the histological subtype. There is evidence from
one paper that LOH of chromosome 6q is an early event in
the course of OC (Zheng et al., 1991), but larger studies will
be needed to resolve this issue.
From several LOH studies, chromosome 6q appears to be
involved in the pathogenesis of other solid tumours. These
studies are summarised in Table IV. In addition to LOH
data, deletions of 6q25-qter have been reported from cyto-
genetic studies of salivary gland adenocarcinoma (Stenman et
al., 1989). When considering all the published data, it is quite
possible that a single gene at 6q27 could have relevance to
the development and progression of a wide variety of tumour
types.
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Figure 4 An analysis of seven tumours using dinucleotide repeat primer pairs is shown. Selected results from PCR amplifications,
with and without 32P, are illustrated below the letters a to I in the bottom third of the figure. In each normal-tumour pair, the
lymphocyte DNA is on the left and the tumour on the right. Terminal deletion/recombination is seen in e and k; interstitial
deletions appear to be present in samples 9 (b & c), 10 (d) and 42 (i & j). When viewed together with Figure 2, g and h suggest that
non-disjunction is the mechanism of chromosomal loss in tumour 29. The range of allele sizes for each primer pair were: D6S202,
130-154 base pairs (bp), commonest allele (c. al.) 148 bp; D6S89, 199-227 bp, c. al 225; D6S109, 169-193 bp, c. al. 187; D6SJ05,
116-138 bp, c. al 128; FTHPJ, 171-181 bp, c. al. 177 & 179.
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Figure 5 Percentage of LOH on 6q is shown for each of the
three pathological grades. Not shown are three tumours which
were graded 2-3 (see Table II) which all showed LOH.
Intriguingly, the ESR gene maps to 6q and genomic DNA,
cDNA and RNA variants of ESR have been demonstrated in
fresh breast cancer and cell lines. Mutations were noted in
the hormone-binding domain in a breast cancer cell line
(Ponlikitmongkol et al., 1988). Insertions, deletions, transi-
tions and exon deletions in fresh tumour RNA were detected
by mutation analysis of PCR amplified cDNA (McGuire et
al., 1992) and an Ala-Val substitution was recognised by an
RNase protection assay (Garcia et al., 1989). Some of these
variants have functional significance, acting in some cases as
a dominant positive receptor, i.e. active in the absence of
oestrogen, and in others as dominant negative: inactive but
inhibiting the function of the normal receptor (McGuire et
al., 1992).
These studies, together with the possible linkage of late-
onset breast cancer in one family to the ESR gene by Zuppan
et al. (1991) and the high frequency of LOH in 6q in breast
cancer (Devilee et al., 1991) suggest that the ESR gene may
be acting as a tumour suppressor in breast cancer. It is
possible that similar variant forms of the ESR gene are also
present in OC; however we did not detect differences by
Southern blotting. This of course, by no means excludes the
possibility that there are mutations in this gene in OC that
result in functionally abnormal proteins. Although reversion
of the malignant melanoma phenotype seen by replacement
of a missing chromosome 6 in microcell transfer experiments
of Trent et al. (1990) could not easily be explained by the
ESR gene functioning as the tumour suppressor in this
cancer, the same system could be used to assess whether wild
type ESR gene transfer results in phenotypic reversion in
hormone-dependent tumours with ESR gene mutations.
This study has confirmed that LOH is a common event on
chromosome 6 in OC and has also provided evidence for the
involvement of three separate regions of the chromosome.
We have demonstrated that PCR-LOH is reliable when
tumour material is reasonably pure, and have used PCR-
LOH to show deletions on 6p that have not been described
previously. The use of PCR may allow archival specimens to
be studied, vastly increasing the potential source of material
particularly from the less common early stage, low grade
tumours and thus the initiating steps in ovarian carcino-
genesis may be elucidated. By studying larger series of
tumours it may be possible to isolate smaller regions of LOH
and hence clone the gene(s) on chromosome 6 that contri-
butes towards the development and progression of ovarian
carcinoma.558 W.D. FOULKES et al.
Table IV LOH on 6q in solid tumours from different tissues
Frequency of Minimal Location ofmarkers used
Cancer studied LOH (%) regions ofLOH (listed in orderfrom 6cen-6qter) References
Ovarian carcinoma 6/10 (60) 6q27a ESR, D6S2, D6S44 Ehlen & Dubeau (1990)
Ovarian carcinoma 9/14 (64) 6q24-qter MYB, ESR Lee et al. (1990)
Ovarian carcinoma 7/23 (30)b 6q27 ESR, D6S2, D6S44 Zheng et al. (1991)
Ovarian carcinoma 5/29 (17)C 6q D6S37 Sato et al. (1991)
Ovarian carcinoma 16/29 (55) 6q24-qter D6S125, HCGA, MYB, ESR, SOD2, This study
TCP10, D6S132, 133, 86, 37
Breast carcinoma 20/42 (48) 6q MYB, D6S37 Devilee et al. (1991)
Breast carcinoma 2/23 (9)C 6q D6S37 Sato et al. (1990)
Renal carcinoma 17/44 (39) 6q27 D6S154, 164, 135, 136, 186, 142, Morita et al. (1991)
156, 161 & 37
Malignant melanoma 10/20 (50) 6q14-25, 6q27d HCGA, MYB, SOD2, ESR, D6S37 Millikin et al. (1991)
Colorectal carcinoma N/A (-33)c 6q D6S44 Vogelstein et al. (1989)
Primitive neuroectodermal 5/21 (24) 6q27f ROS, MYB, ESR, TCP1, D6S2, D6S37 Thomas & Raffel (1991)
aThe6q27assignmentisbasedontwoofthesixtumoursshowingLOH.bThisserieshadadisproportionately largenumberofcaseswithgrade 1 and
2 disease: there was 60% LOH in grade 3 cases. The 6q27 assignment is based on one extra tumour, added to this groups earlier work (row 1). cThe
Japanese grouphaveconsistently found lowerfrequencies ofLOH on6qinbreastandovarian cancer thanothergroups. See textfordiscussion. dThe
minimum regions ofLOH arebasedupon themore recentassignments ofthemarkersused in thisstudy. 'In thisallelotype studyonly thepercentage
LOHwaspublished, thishasbeenestimatedfromFigure laofthepaper.'Onetumourlocalised theminimumregionofLOH to6q27. Anothertumour
showed gain of heterozvgositv with ROS.
The probes were kindly provided by A. Jeffreys (pMS29), J Armour,
(pMS605, pMS614), HGMP Resource Centre (pEFD75.1, p79-2-23,
Ki-rasl, pGST2, phMnSOD4, pJCZ30 and pOR3), E.W. Jabs
(p308), J. Klein (p327A), I. Boime (pCGa), D. Stehelin (pHM2.6), R.
Spielman (pTcr66hl) and G. Vergnaud (CEB3&4). p2lU (D6S114E)
was cloned in this laboratory. Ian Campbell helped with some of the
early work and provided many useful ideas. George Elia performed
the paraffin and frozen tissue sectioning. We thank David Markie for
helpful discussions. We would like to thank the staff at the following
hospitals for providing us with clinical material: St. Bartholomew's,
Homerton, University College, St. Thomas's, Central Middlesex,
Samaritan's, Hammersmith, Elizabeth Garrett Anderson, St. George's,
Royal Marsden, Whittington, Charing Cross (all in London); All
Saints (Chatham, Kent); Barking (Essex); St. Luke's (Guildford,
Surrey); Epsom (Surrey); Ealing (Middlesex) and Pembury (Kent).
Note added in proof
Saito et al. (Cancer Res., 52, 5815-5817, 1992) have recently
reported 52% LOH on chromosome 6q in serous adenocarcinomas
of the ovary. These findings extend their previous work and suggest
that the minimum deleted region in serous adenocarcinomas is a
1.9cM region within 6q27. This result is consistent with our own
findings. It therefore appears that the differences between Japanese
and caucasian ovarian carcinomas is less than might have been
suspected from the original publications.
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